Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802248 | 0.94 | MAPT (0.52) | MAPTKCNH2MEN1KMT2APOLA1 | |
| SCHEMBL7834320 | 0.86 | MAPT (0.53) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6789243 | 0.84 | POLA1 (0.69) | KCNH2MEN1KMT2APOLA1 | |
| SCHEMBL6797030 | 0.84 | KCNH2 (0.53) | MAPTKCNH2MEN1KMT2APOLA1 | |
| SCHEMBL6814897 | 0.83 | MAPT (0.68) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL7854710 | 0.82 | MAPT (0.52) | MAPTKCNH2MEN1KMT2APOLA1 | |
| SCHEMBL7938457 | 0.78 | MAPT (0.67) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6669967 | 0.77 | KCNH2 (0.66) | KCNH2 | |
| SCHEMBL6277664 | 0.77 | KCNH2 (0.54) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6698616 | 0.77 | MAPT (0.47) | MAPTKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727248-B2 | N-(4-CHLOROBENZYL)-8-(3-HYDROXY-1-PROPYNYL)-1-METHYL-6-(4 -MORPHOLINYLMETHYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDE, FOR TREATING INFECTIONS BY HERPES VIRUSES | PHARMACIA & UPJOHN COMPANY | 2004-04-27 | — | — | US | disclosed |
| US-20030149035-A1 | Substituted quinolinecarboxamides as antiviral agents | VAILLANCOURT VALERIE A (US) | 2003-08-07 | — | — | US | disclosed |
| US-6544990-B2 | Substituted quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20020165253-A1 | Substituted quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149035-A1 | Substituted quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, EIF2AK2 | MAPT 3616/4885KCNH2 915/4885MEN1 3830/4885 |
| US-20020165253-A1 | Substituted quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, EIF2AK2 | MAPT 3616/4885KCNH2 915/4885MEN1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.